Jody Lawrence

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus
    Jody Lawrence
    Department of Medicine, Positive Health Program, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA
    N Engl J Med 349:837-46. 2003
  2. ncbi request reprint Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study
    Jody Lawrence
    Department of Medicine, Positive Health Program, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 43:169-78. 2006
  3. ncbi request reprint Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients
    Michael J Kozal
    Yale University Et VA CT Healthcare System, New Haven, CT, USA
    Antivir Ther 11:457-63. 2006
  4. ncbi request reprint A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)
    J Michael Kilby
    University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 194:1672-6. 2006
  5. doi request reprint Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
    HIV Clin Trials 9:91-102. 2008

Detail Information

Publications5

  1. ncbi request reprint Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus
    Jody Lawrence
    Department of Medicine, Positive Health Program, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA
    N Engl J Med 349:837-46. 2003
    ..We compared two strategies for treating patients infected with multidrug-resistant human immunodeficiency virus (HIV)...
  2. ncbi request reprint Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study
    Jody Lawrence
    Department of Medicine, Positive Health Program, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 43:169-78. 2006
    ....
  3. ncbi request reprint Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients
    Michael J Kozal
    Yale University Et VA CT Healthcare System, New Haven, CT, USA
    Antivir Ther 11:457-63. 2006
    ..Little is known about the difference in prevalence of codon 33 mutations and polymorphisms between treatment-naive and treatment-experienced patients, and the effect of codon 33F on PI phenotypic resistance patterns...
  4. ncbi request reprint A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)
    J Michael Kilby
    University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 194:1672-6. 2006
    ..Significant changes were not detected for HIV-specific lymphoproliferative responses in any arm. This exploratory protocol provides useful clinical data for future therapeutic immunization trial design...
  5. doi request reprint Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
    HIV Clin Trials 9:91-102. 2008
    ....